La cadena de opciones muestra datos clave de las opciones de acciones de TG Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para TG Therapeutics..

TG Therapeutics (NASDAQ:TGTX) Bolsa, Cadena de Opciones

TG Therapeutics

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics Inc

CNH Industrial, Parsons and more join S&P MidCap 400

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX – Research Report) and Boston ...

Analysts' Top Healthcare Picks: TG Therapeutics (TGTX), Boston Scientific (BSX)

TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval

Buy Stocks Now, Here Are 3 Categories

Bullish option flow detected in TG Therapeutics (TGTX) with 1,660 calls trading, 1.3x expected, and implied vol increasing almost 3 points to 90.56...

TG Therapeutics call volume above normal and directionally bullish

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on TG Therapeutics (TGTX – Research Report) today and set a price target of $38.00...

Strong Buy Recommendation for TG Therapeutics Driven by Briumvi's Market Potential in RMS Treatment

B. Riley raised the firm's price target on TG Therapeutics (TGTX) to $38 from $34 and keeps a Buy rating on the shares following its high-volume re...

TG Therapeutics price target raised to $38 from $34 at B. Riley

TD Cowen analyst Tara Bancroft initiated coverage of TG Therapeutics (TGTX) with a Buy rating and $50 price target The company's Briumvi is a best-...

TG Therapeutics initiated with a Buy at TD Cowen

ADMA

ADNT

AFRM

AMCX

BHVN

BSQKZ

CADL

CHCT

CSWI

CVGW

EHAB

GOOG

GOOGL

GTLB

HELE

HLNE

INSP

IOVA

IVOG

IVOO

MERC

NVDA

PGNY

PLTR

PSCE

PSCH

PSCT

PYPL

REGL

RILY

SARO

SNOW

TGTX

VIOO

VKTX

VNOM

VREX

WOLF

XMHQ

XMLV

XMMO

ZEUS

News

Health Care

Press Releases

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

Earnings

TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

Comments

TG Therapeutics

TG Therapeutics (TGTX) Opciones

TG Therapeutics (NASDAQ:TGTX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL